Kim Kelderman compensation by year
BIO-TECHNE Summary Compensation Table · all 8 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Salary | $72,500 | $452,400 | $500,000 | $530,000 | $561,800 | $589,890 | $759,511 | $936,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $753,900 | $199,899 | $301,459 | $359,839 | $399,911 | $440,085 | $1,935,433 | $3,929,942 |
| Option awards | $301,603 | $600,028 | $901,452 | $2,079,987 | $1,199,909 | $1,319,921 | $3,858,418 | $1,932,848 |
| Non-equity incentive | $36,250 | $304,796 | $464,000 | $908,102 | $776,445 | $246,717 | $285,394 | $1,318,917 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $1,004 | $8,250 | $8,400 | $8,389 | $9,302 | $9,099 | $13,739 | $33,473 |
| Total | $1,165,256 | $1,565,373 | $2,175,311 | $3,886,317 | $2,947,367 | $2,605,711 | $6,852,495 | $8,151,181 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIO-TECHNE Corp DEF 14A filed September 19, 2025, accession 0001308179-25-000599, and prior-year filings. Open the filing on EDGAR.
How this page was built: the BIO-TECHNE Corp filed document, accession 0001308179-25-000599. Every figure is read from that document and cited to the page and table it appears in. Filed September 19, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 14,196 | $1,017,143 | — |
| PSU | 9,423 | $675,158 | — |
| PSU | 8,191 | $586,885 | — |
| PSU | 6,984 | $500,404 | — |
| PSU | 4,980 | $356,817 | — |
| Option | 12,972 | — | $120.46 |
| Option | 21,704 | — | $94.52 |
| Option | 29,391 | — | $84.61 |
| Option | 11,988 | — | $66.97 |
| Option | 38,252 | — | $52.83 |
| Option | 51,890 | — | $68.54 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BIO-TECHNE Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
36 Form 4 lines since the FY2025 proxy (filed September 19, 2025)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-01 | Tax withholding | — | 2,385 | $72.66 | 80,509 |
| 2026-08-17 | Grant or award derivative | — | 57,590 | $0.00 | 57,590 |
| 2026-08-17 | Grant or award derivative | — | 93,582 | $0.00 | 93,582 |
| 2026-08-15 | Exercise or conversion derivative | — | 588 | $0.00 | 8,835 |
| 2026-08-15 | Exercise or conversion | — | 21,470 | $0.00 | 93,583 |
| 2026-08-15 | Disposition to the issuer derivative | — | 8,319 | $0.00 | 0 |
| 2026-08-15 | Exercise or conversion derivative | — | 554 | $0.00 | 8,319 |
| 2026-08-15 | Disposition to the issuer derivative | — | 22,389 | $0.00 | 1,492 |
The 8 most recent of 36 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
BIO-TECHNE’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kim Kelderman · this page | President and CEO | $8,151,181 |
| James Hippel | Executive Vice President and CFO | $7,027,382 |
| William Geist | President, Protein Sciences | $3,139,299 |
| Matthew McManus | President, Diagnostics and Spatial Biology | $2,846,619 |
| Shane Bohnen | Senior Vice President and General Counsel | $1,980,732 |
Board service
BIO-TECHNE board · FY2025How this board is paid
Company policy: BIO-TECHNE pays directors a $75,000 cash retainer and $200,000 in 50% stock options, 50% restricted stock. As stated in BIO-TECHNE's FY2025 proxy.
The full BIO-TECHNE compensation record
free company briefThis page is one person within BIO-TECHNE's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BIO-TECHNE proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BIO-TECHNE's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIO-TECHNE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TECH
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.